Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases

Archives of Gynecology and Obstetrics

Volumn 283, Issue SUPPL. 1, 2011, Pages

  He, Rong Huan ^a   Yao, Wei Miao ^a   Wu, Li Yan ^b   Mao, Yu Yan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Department of Obstetrics and Gynecology   (China)

Author keywords

Cancer antigen 125; Epithelial ovarian carcinomas; Non malignant gynecological diseases; Tumor marker

Indexed keywords

CA 125 ANTIGEN;

ABORTION; ACUTE ABDOMEN; ADENOMYOSIS; ADULT; ARTICLE; BODY MASS; COMORBIDITY; CONTROLLED STUDY; CYSTADENOMA; ENDOMETRIOSIS; ENDOMETRIUM TUMOR; FEMALE; GYNECOLOGIC DISEASE; HUMAN; HYMEN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY HYPERSTIMULATION; OVARY TERATOMA; PELVIC INFLAMMATORY DISEASE; PELVIS TUMOR; RETROSPECTIVE STUDY; TUBERCULOSIS; UTERUS MYOMA; VAGINA ATRESIA; VAGINA BLEEDING;

ABDOMEN, ACUTE; ADULT; AGE FACTORS; CA-125 ANTIGEN; CASE-CONTROL STUDIES; ENDOMETRIOSIS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; LEIOMYOMA; MEMBRANE PROTEINS; MIDDLE AGED; RETROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 79956098391     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1717-5     Document Type: Article

References (12)

1. Chu CS, Rubin SC (2006) Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 20:307-320 (Pubitemid 43380602)
2. Rosenthal AN, Menon U, Jacobs IJ (2006) Screening for ovarian cancer. Clin Obstet Gynecol 49:433-447 (Pubitemid 44181417)
3. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327-340
4. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS (2009) Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113:775-782
5. Grover S, Koh H, Weideman P, Quinn MA (1992) The effect of the menstrual cycle on serum CA 125 levels: a population study. Am J Obstet Gynecol 167:1379-1381
6. Kobayashi F, Takashima E, Sagawa N, Mori T, Fujii S (1993) Maternal serum CA125 levels in early intrauterine and tubal pregnancies. Arch Gynecol Obstet 252:185-189 (Pubitemid 23131625)
7. Buamah P (2000) Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 75:264-265
8. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, Jurkovic D, Neven P, Van Huffel S, Valentin L (2007) Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 99:1706-1714 (Pubitemid 351767215)
9. Ghaemmaghami F, Karimi ZM, Hamedi B (2007) High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Arch Gynecol Obstet 276:559-561 (Pubitemid 47415758)
10. Muyldermans M, Cornillie FJ, Koninckx PR (1995) CA125 and endometriosis. Hum Reprod Update 1:173-187
11. Johansson J, Santala M, Kauppila A (1998) Explosive rise of serum CA 125 following the rupture of ovarian endometrioma. Hum Reprod 13:3503-3504 (Pubitemid 29002648)
12. Buyukbayrak EE, Ozyapi AG, Karsidag YK, Pirimoglu ZM, Unal O, Turan C (2008) Imperforate hymen: a new benign reason for highly elevated serum CA 19.9 and CA 125 levels. Arch Gynecol Obstet 277:475-477